Prelude Capital Management’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-13,072
| Closed | -$1.95M | – | 1085 |
|
|
2024
Q3 | $1.95M | Buy |
13,072
+8,342
| +176% | +$1.25M | 0.12% | 201 |
|
|
2024
Q2 | $645K | Buy |
+4,730
| New | +$645K | 0.04% | 380 |
|
|
2024
Q1 | – | Sell |
-6,500
| Closed | -$819K | – | 1196 |
|
|
2023
Q4 | $819K | Sell |
6,500
-700
| -10% | -$88.2K | 0.05% | 288 |
|
|
2023
Q3 | $674K | Buy |
7,200
+800
| +13% | +$74.9K | 0.04% | 317 |
|
|
2023
Q2 | $571K | Sell |
6,400
-1,600
| -20% | -$143K | 0.04% | 355 |
|
|
2023
Q1 | $858K | Buy |
8,000
+700
| +10% | +$75.1K | 0.05% | 306 |
|
|
2022
Q4 | $892K | Buy |
7,300
+2,300
| +46% | +$281K | 0.05% | 375 |
|
|
2022
Q3 | $516K | Sell |
5,000
-1
| -0% | -$103 | 0.02% | 620 |
|
|
2022
Q2 | $465K | Buy |
5,001
+2,701
| +117% | +$251K | 0.01% | 718 |
|
|
2022
Q1 | $270K | Sell |
2,300
-2,700
| -54% | -$317K | 0.01% | 874 |
|
|
2021
Q4 | $673K | Buy |
5,000
+2,996
| +150% | +$403K | 0.02% | 644 |
|
|
2021
Q3 | $319K | Buy |
2,004
+4
| +0.2% | +$637 | 0.01% | 837 |
|
|
2021
Q2 | $263K | Buy |
+2,000
| New | +$263K | 0.01% | 1009 |
|
|
2020
Q4 | – | Sell |
-3,340
| Closed | -$515K | – | 807 |
|
|
2020
Q3 | $515K | Buy |
+3,340
| New | +$515K | 0.02% | 284 |
|